Fungal infections affect millions of people globally and are often unreceptive to conventional
topical or oral preparations because of low drug bioavailability at the infection site, lack of …

The development of dissolving microneedles (DMN) is one of the advanced technologies in
transdermal drug delivery systems, which precisely deliver the drugs through a rapid …

Subcutaneous fungal infection is often difficult to be treated by the conventional topical
application or oral intake of antifungal agents because of low drug bioavailability to the …

Cutaneous leishmaniasis (CL) is a significant public health problem caused by different
species of Leishmania parasites. Due to low skin permeability, the development of an …

The administration of conventional dosage forms of itraconazole (ITZ) for cutaneous
candidiasis treatment is limited by its poor aqueous solubility and the deep location of …

Recently an increase in both the prevalence and incidence of invasive fungal infections
have been reported. The number of fungal species that can cause systemic mycoses are …

Invasive fungal infections (IFIs) represent a growing public concern for clinicians to manage
in many medical settings, with substantial associated morbidities and mortalities. Among …

Conventional oral administration of antifilariasis drugs results in nonspecific targeting of the
drugs and the intradermal delivery of nanoparticles with sizes of< 100 nm could be used to …

During the last two decades, the occurrence of fungal infections either superficial or systemic
has been increasing. Moreover, fungal infections become more difficult to treat when they …

The present studies were designed to develop a microemulsion (ME) formulation of
Amphotericin B (Amp B) for the treatment of invasive fungal infections. The oil phase was …